CN1569161A - Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process - Google Patents
Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process Download PDFInfo
- Publication number
- CN1569161A CN1569161A CN 200410022513 CN200410022513A CN1569161A CN 1569161 A CN1569161 A CN 1569161A CN 200410022513 CN200410022513 CN 200410022513 CN 200410022513 A CN200410022513 A CN 200410022513A CN 1569161 A CN1569161 A CN 1569161A
- Authority
- CN
- China
- Prior art keywords
- preparation
- concentrated
- ethanol
- relative density
- supernatant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 62
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 27
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 23
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title abstract description 9
- 230000008569 process Effects 0.000 title abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 420
- 239000003814 drug Substances 0.000 claims description 75
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 61
- 239000006228 supernatant Substances 0.000 claims description 58
- 239000007924 injection Substances 0.000 claims description 37
- 238000002347 injection Methods 0.000 claims description 37
- 238000011282 treatment Methods 0.000 claims description 34
- 239000000843 powder Substances 0.000 claims description 32
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 29
- 241000628997 Flos Species 0.000 claims description 27
- 239000008187 granular material Substances 0.000 claims description 27
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 21
- 241000180649 Panax notoginseng Species 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000003826 tablet Substances 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000006187 pill Substances 0.000 claims description 12
- 239000000080 wetting agent Substances 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 11
- 239000007919 dispersible tablet Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 238000000465 moulding Methods 0.000 claims description 11
- 239000008188 pellet Substances 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 239000007901 soft capsule Substances 0.000 claims description 9
- 206010013786 Dry skin Diseases 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 229920000881 Modified starch Polymers 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 6
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 238000005453 pelletization Methods 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000011812 mixed powder Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000008227 sterile water for injection Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000241550 Cyathula Species 0.000 abstract 1
- 241000132521 Erigeron Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 23
- 229940079593 drug Drugs 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 206010002383 Angina Pectoris Diseases 0.000 description 9
- 230000004075 alteration Effects 0.000 description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 7
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 7
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 7
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 7
- 229940074393 chlorogenic acid Drugs 0.000 description 7
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 7
- 235000001368 chlorogenic acid Nutrition 0.000 description 7
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 7
- 238000005550 wet granulation Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 241000721047 Danaus plexippus Species 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000002932 luster Substances 0.000 description 5
- 239000009064 mailuoning Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 206010008132 Cerebral thrombosis Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 229930182486 flavonoid glycoside Natural products 0.000 description 4
- 150000007955 flavonoid glycosides Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 201000001068 Prinzmetal angina Diseases 0.000 description 3
- 208000007718 Stable Angina Diseases 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 208000009325 Variant Angina Pectoris Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000007799 cork Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000001723 fibrinogenic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 230000007226 seed germination Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process, wherein the preparation is prepared from two or three from honeysuckle, achyranthes and cyathula root, radix scrophulariae, herb of shortcape fleabane and pseudo-ginseng.
Description
Technical field: the present invention is a kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof, belongs to technical field of Chinese medicine.
Technical background: cardiovascular and cerebrovascular disease such as coronary heart disease, cerebral thrombosis, alzheimer disease etc. all are one of diseases that M ﹠ M is the highest in the world today, are dead first causes, are the No.1 killers of human health.Prevent and treat purpose in order to reach, a large amount of research has been done by many inventors and medicine enterprise, and the product of some treatments also is provided; As: number of patent application is: 03113176, name is called " application of TONGSAIMAI extractum in preparation treatment apoplexy medicine " and number of patent application is: 03119593, name is called " preparation method of injecting Mailuoning oral solid formulation " and is the medicine for the treatment of this respect disease; But these two kinds of products have all used this medical material of Herba Dendrobii; The subject matter that its exists is: on the one hand, because this medical material of Herba Dendrobii is in evolution of long period of time develops, seed germination rate is low, the growth conditions harshness is added human long-term a large amount of excavating, occurring in nature existence seldom, endangered, classified as the second class protection plant by country; So there is certain problem in their crude drug source; On the other hand, increase year by year, so need provide more to market, obvious results, the treatment medicine of being free from side effects owing to suffer from the patient of cardiovascular and cerebrovascular disease.In view of such circumstances, seek that a kind of medical material compatibility is simple, therapeutic effect is desirable, does not have toxic and side effects, the thing that preparation technology's rational and effective medicine preparation has become people to be badly in need of solving.
Summary of the invention: the objective of the invention is to: a kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof is provided; Do not use this medical material of Herba Dendrobii in this medicine, the medicine of making can more effectively be treated the disease that cardiovascular and cerebrovascular disease causes blood supply insufficiency to cause as: reasons such as coronary heart disease, cerebral thrombosis, alzheimer disease etc. contract because of blood vessel is narrow, blood flow minimizing equally; The present invention adopts Flos Lonicerae according to motherland's traditional Chinese medicine theory, Radix Achyranthis Bidentatae, and Radix Scrophulariae, one or both compatibilities in Herba Erigerontis or the Radix Notoginseng are made preparation; It has heat clearing away YIN nourishing, activating blood circulation to dissipate blood stasis, TONGMAI SHULUO, has effects such as blood vessel dilating, microcirculation improvement, blood flow increasing and anticoagulation, thrombus dissolving.For example coronary heart disease is that coronary atherosclerosis causes myocardial ischemia, anoxia and the heart disease that causes, and compatibility share, and can play to improve the myocardial metabolism effect, increase coronary flow, and the blood that improves cardiac muscle is provided with the effect of allevating angina pectoris.The present invention has curative effect preferably for treating cardiovascular and cerebrovascular disease such as coronary heart disease, angina pectoris, arrhythmia, cerebral thrombosis, alzheimer disease etc.And the present invention is pure Chinese medicinal preparation, but the little patients life-time service of its untoward reaction; The present invention has simultaneously also protected Chinese Second Class Key Protected Plant, helps normal, the harmonious development of natural environment.
The present invention constitutes like this: calculate according to components by weight percent, it is mainly by Flos Lonicerae 10-80 weight portion, Radix Achyranthis Bidentatae 15-85 weight portion, and Radix Scrophulariae 15-80 weight portion, one or both 20-85 weight portions in Herba Erigerontis, the Radix Notoginseng are made.Say that accurately it is mainly by Flos Lonicerae 50 weight portions, Radix Achyranthis Bidentatae 50 weight portions, Radix Scrophulariae 50 weight portions, one or both 50 weight portions in Herba Erigerontis, the Radix Notoginseng are made.Preparation of the present invention is: injection, comprising: injection, powder pin, freeze-dried powder, tablet, dispersible tablet, capsule, soft capsule, pellet, granule, pill, powder, drop pill, slow releasing preparation, controlled release preparation, oral liquid, gel, soft extract, extractum and membrane.Preferred formulation of the present invention is: injection, comprising: injection, powder pin, freeze-dried powder, tablet, dispersible tablet, pellet, soft capsule, capsule, granule, drop pill, gel.Preparation method of the present invention: the medicine pulverizing is added 3～10 times of water gagings soaked 1～5 hour, decoct each 1～3 hour 1～5 time, filter, merging filtrate is concentrated into relative density 1.10～1.20, adding ethanol is 60% to containing the alcohol amount, leaves standstill, and gets supernatant, reclaim ethanol and be concentrated into relative density 1.20～1.40, adding ethanol is 80% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol, get extractum, make different preparations then respectively.Say accurately: medicine is pulverized, add 6 times of water gagings and soaked 2 hours, decoct each 1.5 hours 2 times, filter, merging filtrate is concentrated into relative density 1.16, and adding ethanol is 60% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol, add the dissolving of injection water, regulate pH value to 7.5～8.0 with 10% sodium hydroxide solution, add injection water and 0.1% needle-use activated carbon, the mixed solution heated and boiled filters, add sterile water for injection to full dose, add 10mg/ml mannitol again, vacuum lyophilization or aseptic filtration or spray drying or in organic solvent recrystallization, promptly get injection.
Medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct 2 times, each 1.5 hours, filter merging filtrate, be concentrated into relative density 1.16, adding ethanol is 60% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol, add the dissolving of injection water, regulate pH value to 7.5～8.0 with 10% sodium hydroxide solution, add injection water and 0.1% needle-use activated carbon, the mixed solution heated and boiled filters, and adds 0.1% sodium pyrosulfite and water for injection again to certain volume, filter, fill, sterilization promptly gets injection.
Medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct each 1.5 hours 2 times, filter, merging filtrate is concentrated into relative density 1.16, and adding ethanol is 60% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leaves standstill, and gets supernatant, reclaim ethanol, add 2% low-substituted hydroxypropyl cellulose, it is moistening to add water, make granule, drying promptly gets granule.
Medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct 2 times, each 1.5 hours, filter merging filtrate, be concentrated into relative density 1.16, adding ethanol is 60% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol, extractum adds pregelatinized Starch, (the pregelatinized Starch: be 1: 1 lactose=1: 2) of the mixed powder of lactose with the principal agent ratio, add 2% crospolyvinylpyrrolidone, mixing is that wetting agent is granulated with 95% ethanol, place, 60 ℃ of dryings, granulate adds 0.5% magnesium stearate and 5% crospolyvinylpyrrolidone, tabletting promptly gets dispersible tablet.
Medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct 2 times; each 1.5 hours, filter merging filtrate; be concentrated into relative density 1.16; adding ethanol is 60% to containing the alcohol amount, leaves standstill, and gets supernatant; reclaim ethanol and be concentrated into relative density 1.36; adding ethanol is 80% to containing the alcohol amount, leaves standstill, and gets supernatant; reclaim ethanol; dried cream powder is broken, and extract powder adds microcrystalline Cellulose, and (extract powder: microcrystalline Cellulose=2: 1), concentration is that 30～50% ethanol are wetting agent; concentration is that 3～5%PVP is a binding agent; put in the coating pelletizing machine, regulate coating granulator engine speed 100～120r; min; the blow rate required 10 * 10L/ml prepares Chinese medicine pellet, and molding time is 10～15min; after preparation finishes; continue round as a ball 1h, regulate 50 ℃～60 ℃ dryings of hot blast speed immediately, promptly get pellet.
Medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct 2 times, each 1.5 hours, filter merging filtrate, be concentrated into relative density 1.16, adding ethanol is 60% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leaves standstill, get supernatant, triglyceride=1: 55), 5%-10% glycerol (extractum: glycerol=1: 10) reclaim ethanol, dried cream powder is broken, and extract powder adds triglyceride (extractum:, mixing, making content, is the capsule material with the gelatin, pill, drying promptly gets soft capsule.
Medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct each 1.5 hours 2 times, filter, merging filtrate is concentrated into relative density 1.16, and adding ethanol is 60% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol, add 2% low-substituted hydroxypropyl cellulose, it is moistening to add water, makes granule, drying, add 2% carboxymethyl starch sodium, tabletting promptly gets tablet.
Medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct each 1.5 hours 2 times, filter, merging filtrate is concentrated into relative density 1.16, and adding ethanol is 40～70% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 70～90% to containing the alcohol amount, leaves standstill, and gets supernatant, reclaim ethanol, add 3% methylcellulose, add the moistening back of water and granulate, mixing incapsulates, and promptly gets capsule preparations.
According to Chinese medical theory, Flos Lonicerae heat-clearing and toxic substances removing, wind-heat dissipating; The Radix Achyranthis Bidentatae invigorating the liver and kidney, eliminating blood stasis and inducing menstruation, both are monarch drug altogether; Radix Scrophulariae removing heat from blood YIN nourishing is ministerial drug; Three's compatibility, effects such as blood vessel dilating, microcirculation improvement, blood flow increasing and anticoagulation, thrombus dissolving; If assistant is with Herba Erigerontis, can play blood circulation promoting and blood stasis dispelling, the effect of dredge the meridian passage, breviscapine improves the permeability of blood brain screen by improving blood vessel circulation cerebral blood flow increasing amount, reducing vascular resistance, dilating coronary blood vessel and peripheral blood vessel, alleviate myocardial oxygen consumption, increase the myocardial nutrition blood flow, the enhancing body hypoxia-bearing capability, can strengthen the sequela due to the prescription therapeutic cardiovascular and cerebrovascular vessel, for example the effect of paralysis etc.; If assistant is with Radix Notoginseng, dissipating blood stasis stops blooding, and subduing swelling and relieving pain, its flavonoid glycoside are significantly increased crown arteries and veins blood flow, and decreasing heart rate and minimizing myocardial oxygen consumption, compatibility use and strengthen the anginal effect of treatment.The present invention has curative effect preferably for treating cardiovascular and cerebrovascular disease such as coronary heart disease, angina pectoris, arrhythmia, cerebral thrombosis, alzheimer disease etc.And the present invention is pure Chinese medicinal preparation, but the little patients life-time service of its untoward reaction.Crude drug source required for the present invention is abundant, and the detailed processing technology of several formulations is provided, and can be directly used in and instruct actual production.
Compared with prior art, simple, preparation method science, reasonable that prescription constitutes, the formulation products that obtains can effectively be prevented and treated the disease for the treatment of cardiac and cerebral vascular diseases; Especially breviscapine can strengthen the sequela due to the prescription therapeutic cardiovascular and cerebrovascular vessel, for example the effect of paralysis etc.; The contained flavonoid glycoside of Radix Notoginseng is significantly increased crown arteries and veins blood flow, and decreasing heart rate and minimizing myocardial oxygen consumption, compatibility use and strengthen the anginal effect of treatment.Chlorogenic acid is one of main effective ingredient of monarch drug Flos Lonicerae, and is unstable in aqueous solution, easy oxidation Decomposition, and the applicant finds by a large amount of experiments: the problem that can solve said preparation stability with sodium pyrosulfite; The applicant finds that also pH value directly influences stability, the clarity of the contained flavonoid glycoside of Radix Notoginseng in injection, has only the stability of product when pH value is 7.5-8.0, clarity best.Preparation of the present invention also can be used for treating hepatorenal syndrome, diabetes, pulmonary heart disease etc.In the side, do not re-use the plant of this state guarantee of Herba Dendrobii; Reached the purpose of invention.
The applicant has carried out a series of experiments, can prove that medicine provided by the invention has effective effect;
Experimental example 1: extraction process screening
One of main effective ingredient of monarch drug Flos Lonicerae is a chlorogenic acid, has the effect of antiinflammatory, antiviral, blood fat reducing, immunomodulating, hepatic cholagogic etc.; One of main active of monarch drug Radix Achyranthis Bidentatae is an oleanolic acid, has hepatoprotective, blood sugar lowering, blood fat reducing, antiinflammatory, antioxidation, and both are important onset compositions of product of the present invention, and extraction process directly influences the curative effect and the quality of product.
Oleanolic acid % chlorogenic acid %
Decoction and alcohol sedimentation technique 0.75 0.62
Reflux extraction method 0.63 0.52
Ethanol extract from water precipitation 0.48 0.50
The result shows: extraction process of the present invention is rationally feasible, the effective component extraction rate height.
The screening of experimental example 2 moulding processs
Moulding process is directly connected to the character and the absorption in vivo utilization of product, is key technology of the present invention.
Average disintegration time: adopting changes the basket method, and lift disintegration tester, tablet or capsule are got 6 units, calculates the meansigma methods of passing through the screen cloth time fully.
Melting: get granule 10g, add 20 times of hot water, stirred 5 minutes, observe immediately.
(1) granule
1. adjuvant (consumption 3%) starch slurry arabic gum low-substituted hydroxypropyl cellulose
It is moist and dissolve the little tide of distortion granule that particle appearance is dissolved distortion and adhesion
Melting all dissolves t＜30s and all dissolves t＞30s and all dissolve t＜30s
The granulation complexity is easily granulated and the uniform particles difficulty is granulated, granule is crossed sticking easily the granulation and uniform particles
2. low-substituted hydroxypropyl cellulose is to the influence (n=3) of melting
Low-substituted hydroxypropyl cellulose consumption (%) 123
Melting all dissolves t＞30s and all dissolves t=20s and all dissolve=
25s
(2) capsule
1. binder dosage % outward appearance disintegration (min)
Methylcellulose 5 granules little damp 30
Starch 5 is moist and dissolve distortion 45
Low-substituted hydroxypropyl cellulose 5 granules little damp 40
2. methylcellulose is to EFFECT OF CORK STOPPER (n=3)
Methylcellulose consumption (%) 12359
Disintegration (min) 40 25 20 31 30
(3) tablet: the screening of disintegrating agent
1. disintegrating agent consumption % outward appearance disintegration (min)
5 loose 29 of dry starch
Carboxymethyl starch sodium 5 hardness are good, glossy degree 30
Carboxymethyl cellulose 5 hardness are good, and bright and clean 55
2. the carboxymethyl starch sodium consumption is to EFFECT OF CORK STOPPER (n=3)
Carboxymethyl starch sodium consumption (%) 12357
Disintegration (min) 42 22 29 35 38
(4) injection: chlorogenic acid is one of main effective ingredient of monarch drug Flos Lonicerae, and is unstable in aqueous solution, easy oxidation Decomposition, and the selection of antioxidant is stable most important to product.The applicant finds that also pH value directly influences stability, the clarity of the contained flavonoid glycoside of Radix Notoginseng in injection.
1. the selection of antioxidant: (PH7.5-8.0) 0 month March
Antioxidant consumption % color and luster clarity chlorogenic acid (mg/ml) color and luster clarity chlorogenic acid (mg/ml)
--faint yellow clear and bright 3.48 faint yellow clear and bright 3.13
Sodium sulfite 0.1 yellowish aberration 3.42 yellowish-brown aberration 3.22
Sodium pyrosulfite 0.1 faint yellow clear and bright 3.50 faint yellow clear and bright 3.24
Thiourea 0.1 faint yellow clear and bright 3.41 faint yellow clear and bright 3.12
Sodium sulfite 0.2 faint yellow clear and bright 3.49 yellowish-brown aberration 3.41
Sodium pyrosulfite 0.2 faint yellow clear and bright 3.45 yellowish aberration 3.28
Thiourea 0.2 faint yellow clear and bright 3.57 yellowish-brown aberration 3.21
2. the selection of pH value: 0 month March
PH value clarity color and luster clarity color and luster
6.0 the yellowish-brown aberration yellowish-brown of difference
6.5 the yellowish-brown aberration yellowish-brown of difference
7.0 the yellowish aberration yellowish-brown of difference
7.5 it is bright faint yellow clear and bright faint yellow
8.0 it is clear and bright faint yellow clear and bright faint yellow
8.5 bright yellowish aberration is faint yellow
(5) injectable powder: the selection of excipient: injectable powder more helps the stable of chlorogenic acid, and is even for guaranteeing dried crystallization, the color and luster unanimity, and fine texture has good physical strength and dissolubility faster, and the applicant has carried out the screening of excipient.
Amount of excipient (mg/ml) clarity mouldability dissolution velocity (s)
--difference shrinks 40
Mannitol 5 well shrinks 35 slightly
Mannitol 10 good nothings shrink 15
Glucose 5 good coarse 30
Glucose 10 well shrinks 20 slightly
Glycine 5 differences coarse 36
Glycine 10 differences coarse 32
(6) dispersible tablet: dispersible tablet be meant meet water rapidly disintegrate form the non-coated tablet of uniform viscosity suspension, the advantage of its double all tablet and liquid preparation; Except having the ordinary tablet good stability, be easy to carry, outside the advantages such as taking convenience, also have the bioavailability advantage of higher, both can directly swallow, also can drop into disintegrate rapidly in the water, take after forming uniform suspension, be specially adapted to the patient of difficulty that swallows, the applicant is in order to improve bioavailability of medicament, facilitate patients, developed dispersible tablet.
1. preliminary disintegrating agent screening: disintegrating agent is 5% of tablet weight, and mixing is that wetting agent is granulated with 95% ethanol, place, and 60 ℃ of dryings, granulate adds magnesium stearate 0 5%, and tabletting is surveyed disintegration.
Sequence number disintegrating agent disintegration/min
1 crosslinked CMC-Na 26.85
2 CMS-Na 27.83
3 PVPP 30.22
4 L-HPC 45.01
5 MCC102 46.14
6 MCC101 48.16
7 HPMC 60.07
According to above result, select sequence number 1,2,3 further to optimize.
2. preparation technology improves (adding disintegrating agent): getting extractum, is that wetting agent is granulated with 95% ethanol, place, and 60 ℃ of dryings, granulate adds disintegrating agent and is 5% of tablet weight, magnesium stearate 05%, tabletting, promptly.Survey disintegration.
Sequence number disintegrating agent disintegration/min
1 crosslinked CMC-Na 11.06
2 CMS-Na 23.14
3 PVPP 7.51
Test the result factually, selecting PVPP (crospolyvinylpyrrolidone) is disintegrating agent.
3. the further screening of adjuvant and technology
Sequence number method of granulating disintegrating agent adding method/% diluent/% disintegration
/min
In add and add the pregelatinized Starch lactose
1 direct compression of full-powder 5 4.5 9.17
2 wet granulations 5 4.5 5.15
3 wet granulations 55 4.5 17.03
4 wet granulations 5 4.5 31.32
5 wet granulations 55 2.25 2.25 2.51
6 wet granulations 55 3.0 1.5 19.03
7 wet granulations 25 1.5 3.0 1.54
8 wet granulations 52 1.5 3.0 7.53
The result shows, determine prescription 7, promptly diluent is pregelatinized Starch in the prescription: lactose (1: 2) is (1: 1) with the principal agent ratio, disintegrating agent be crospolyvinylpyrrolidone (in add 2%, add 5%), lubricant is that the dispersible tablet performance that makes of magnesium stearate (0.5%) is good.
(7) micropill
The equivalent extract powder adds different excipient, different binding agent and wetting agent respectively, adopts fluidized bed granulation technology and prepared micropill.Be that extract powder adds excipient, binding agent and wetting agent, put in the coating pelletizing machine, regulate coating granulator engine speed 100～120r/min, the blow rate required 10 * 10L/ml and prepare Chinese medicine pellet.Preparation continues round as a ball 1h after finishing.Regulating 50 ℃～60 ℃ dry certain hours of hot blast speed immediately gets final product.
Extract powder excipient wetting agent binding agent molding time (min) appearance character micropill size
G kind consumption g concentration kind concentration kind
20 anhydrous 30% Mel, 10～15min adhesion is agglomerating can not molding
20 nothings, 30～50% ethanol, 20% sucrose, 15～20min adhesion is agglomerating can not molding
20 nothings, 70～90% ethanol, 1～5% PVP, 15～20min adhesion is agglomerating can not molding
20 nothings, 30～50% ethanol, 3～5% PVP, 15～20min adhesion is agglomerating can not molding
20 starch, 10 30～50% ethanol, 1～5% PVP, 10～15min becomes irregular not easy-formation
The spherical rounding 100% of 20 microcrystalline Cellulose, 10 30～50% ethanol, 3～5% PVP, 10～15min is crossed 18 orders
Sieve
20 microcrystalline Cellulose, 10 70～90% ethanol, 3～5% PVP, 15～20min becomes irregular not easy-formation
The spherical rounding 88% of 20 starch, 10 30～50% ethanol, 3～5% PVP, 15～20min is crossed 18 orders
Sieve
The result shows that best prescription is an extract powder: microcrystalline Cellulose=2: 1, concentration are that 30～50% ethanol are wetting agent, and concentration is that 3～5%PVP is a binding agent, molding time is 10～15min, make the spherical rounding of micropill appearance character, all, functional by 18 order pharmacopeia sieve.
(8) soft capsule
Each soft capsule was deposited 6 months in 40 ℃,, measured its disintegration time in the simulated gastric fluid of 100rpm at 37 ℃.
The selection of adjuvant:
Prescription dry extract (g) filler disintegration time
1 10 polyethylene glycol 6000s (550g) 1.1h
2 10 polyethylene glycol 6000s (550g)+5%-10% glycerol (100g) 20min
3 10 polyethylene glycol 6000s (400g) 45min
4 10 triglycerides (550g) 40min
5 10 triglycerides (550g) ± 5%-10% glycerol (100g) 15min
6 10 triglycerides (400g) 30min
By the result as seen, best prescription is dry extract 10g, triglyceride 550g, 5%-10% glycerol 100g, and glycerol can reduce the induration of polyethylene glycol 6000.
The result shows, adopts the selected prepared quality of the pharmaceutical preparations of adjuvant of the present invention stable, controlled; Make that the formed product of gained of the present invention is good.
The clinical efficacy of sequela due to the experimental example 3 treatment cardiovascular and cerebrovascular vessel
Object: 45 routine patients are out-patient department's inpatient, are divided into 3 groups, wherein male 24 examples, women 21 examples, age 35-75 year, disease time 2-15 days.All cases all have quadriplegia.Paralyzed limbs muscular strength 0-1 level 4 examples wherein, 2-4 level 23 examples have aphasiac 15 examples, and person's 22 examples clearly owed in language, and the person of coughing of choking 8 examples are arranged, and hyperpietic's 21 examples are arranged, person's 14 examples that have the headache and dizzy.30 examples are all through head CT. check to confirm that 10 example companion brain atrophys are wherein arranged.Method: treat 1 group: oral liquid of the present invention (Flos Lonicerae, Radix Achyranthis Bidentatae, Radix Scrophulariae, Herba Erigerontis) 3 times on the 1st, each 20ml, 2 weeks of the course of treatment.Treat 2 groups: oral liquid of the present invention (Flos Lonicerae, Radix Achyranthis Bidentatae, Radix Scrophulariae, Radix Notoginseng) 3 times on the 1st, each 20ml, 2 weeks of the course of treatment.Treat 3 groups: MAILUONING oral liquid (Flos Lonicerae, Radix Achyranthis Bidentatae, Radix Scrophulariae, Herba Dendrobii) 3 times on the 1st, each 20ml, 2 weeks of the course of treatment.
Efficacy determination: be divided into according to the 3rd the cerebrovascular meeting standard in the whole nation: 1. be almost recovered: consciousness recovery is normal, and muscular strength reaches the 4-5 level, takes care of oneself; 2. produce effects: hemiplegia, aphasia are obviously recovered, and muscular strength improves more than 2 grades, and 3. effective: subjective symptoms alleviates, and muscular strength improves 8 grades, but can't take care of oneself; 4. invalid: front and back symptom no change.
Result: the produce effects that is almost recovered enabledisable
Treat 1 group 10 122
Treat 2 group 8412
Treat 3 group 7314
The result shows, contains the preparation of the present invention of Herba Erigerontis, can effectively treat the sequela due to the cardiovascular and cerebrovascular vessel behind the drug regimen compatibility.
Experimental example 4: treat anginal clinical efficacy
Physical data: be divided into 3 groups at random with having met the 60 routine patients of WHO since 2000 about angina diagnostic criteria.Treat 1 group of 20 example, male 10 examples, women 10 examples; 45～74 years old age; Stable angina pectoris 12 examples wherein, unstable angina pectoris 5 examples, variant angina pectoris 3 examples.Treat 2 group of 20 example, male 11 examples, women 9 examples; 50～81 years old age; Stable angina pectoris 14 examples wherein, unstable angina pectoris 5 examples, variant angina pectoris 1 example.Treat 3 group of 20 example, male 12 examples, women 8 examples; 47～74 years old age; Stable angina pectoris 12 examples wherein, unstable angina pectoris 4 examples, variant angina pectoris 4 examples.Two groups of ages, sex and angina pectoris type no difference of science of statistics.
Therapeutic Method: treat 1 group: oral liquid of the present invention (Flos Lonicerae, Radix Achyranthis Bidentatae, Radix Scrophulariae, Radix Notoginseng) 3 times on the 1st, each 20ml, 2 weeks of the course of treatment.Treat 2 groups: oral liquid of the present invention (Flos Lonicerae, Radix Achyranthis Bidentatae, Radix Scrophulariae, Herba Erigerontis) 3 times on the 1st, each 20ml, 2 weeks of the course of treatment.Treat 3 groups: MAILUONING oral liquid (Flos Lonicerae, Radix Achyranthis Bidentatae, Radix Scrophulariae, Herba Dendrobii) 3 times on the 1st, each 20ml,, 2 weeks of the course of treatment.Three groups are all treated 10d is 1 course of treatment.
The efficacy assessment standard produce effects: transference cure or basic the disappearance, electrocardiogram recovers normally or is roughly normal.Effectively: paresthesia epilepsy number of times, degree, persistent period obviously alleviate, ECG ST section rise 0.05mV is above or negative T wave shoals or by smooth become upright; Invalid: symptom and electrocardiogram do not have significant change after 2 courses of treatment.
Group produce effects enabledisable
Treat 1 group 15 41
Treat 2 group 11 45
Treat 3 group 956
The result shows, contains the preparation of the present invention of Radix Notoginseng, and compatibility of drugs can effectively be treated angina pectoris after using.
Experimental example 5: to the influence of blood stasis model rabbit blood rheological characteristic
Test 1 group: 'Mailuoning ' injection; Test 2 groups: injection of the present invention (Flos Lonicerae, Radix Achyranthis Bidentatae, Radix Scrophulariae, Herba Erigerontis, Radix Notoginseng);
40 of rabbit are divided into 5 groups at random, and 8 every group, ♀ ♂ half and half is respectively blank group, model control group, positive drug control group and experimental group.Each treated animal elder generation auricular vein is injected (iv) administration.Blank and model control group injecting normal saline (NS) 1ml/kg, positive drug group iv puerarin injection 30mg/kg (being made into 30mg/ml) with NS, experimental group is injected the medicinal liquid (being made into NF) of 0.25mg/ml respectively, dosage is 1ml/kg, two weeks of successive administration (14d), in administration the 2nd, 13d, except that the blank group, each rabbit is annotated 10% high molecular dextran 5ml/kg through auricular vein respectively, every day twice, causes blood stasis model.After the last administration, inject 10% high molecular dextran 5ml/kg once more, behind the 15min, heart is taked fasting blood 6ml, carrying out hemorheology index detects, wherein platelet aggregation rate adopts turbidimetry for Determination: the rotary cone-plate viscosity apparatus mensuration of other employing LBY-N6A+ with LBY-NJ2 type platelet aggregation instrument.
1. to rabbit platelet aggregation and fibrinogenic influence
To rabbit platelet aggregation and fibrinogenic influence (x ± s, n=6)
Group dosage (ml/kg) body weight (kg) platelet aggregation (%) Fibrinogen (g/L)
Blank group-2.31 ± 0.15 15.54 ± 2.46 2.53 ± 1.16
Model group-2.45 ± 0.08 38.27 ± 15.05 2.97 ± 1.41
Positive drug group 3 2.37 ± 0.11 15.74 ± 3.47 2.55 ± 1.83
Test 1 group 2 2.32 ± 0.15 14.86 ± 2.38 2.60 ± 0.94
Test 2 group 2 2.43 ± 0.13 14.28 ± 3.16 2.52 ± 1.85
2. to the influence of rabbit erythrocyte aggregation
Group dosage ml/kg aggregate index rigidity index deformation index electrophoresis index
Blank group-1.91 ± 0.22 3.43 ± 0.42 0.71 ± 0.05 4.32 ± 0.46
Model group-2.92 ± 0.70 4.62 ± 2.16 0.76 ± 0.16 6.75 ± 2.14
Positive drug group 3 2.35 ± 0.55 2.96 ± 0.88 0.64 ± 0.15 5.38 ± 2.24
Test 1 group 2 2.27 ± 0.21 2.94 ± 0.61 0.66 ± 0.13 5.17 ± 0.64
Test 2 group 2 2.28 ± 0.33 2.93 ± 0.81 0.64 ± 0.12 4.97 ± 0.60
The result shows that preparation curative effect of the present invention is not less than 'Mailuoning ' injection, and the Herba Dendrobii that does not use crude drug source to be difficult for.
Experimental example 6: to the treatment of rat experiment liver cirrhosis
Male Wistar rat, body weight 200～250g is divided into 3 groups; Test 1 group: the Hepatocirrhosis Model matched group, test 2 groups: the normal control group, test 3 groups: injection group of the present invention.Remove 2 groups of experiments, all the other experimental grouies adopt complex disease because of stimulating the system Hepatocirrhosis Model, promptly raise with low albumen high lipid diet, and 30% ethanol is beverage, intravenous injection CCL
4Treatment group beginning in second day administration, once a day, lumbar injection injection group of the present invention 0.05ml/100g, matched group injection equivalent normal saline.In 6～8 of experiment every group of execution at the 2nd, 4,6,8 weekends animals.Get fritter hepatic tissue 2% sodium cacodylate buffer glutaraldehyde and fix, make electron microscope specimen and observe, all the other hepatic tissue 95% dehydration of alcohols, the acetone defat is carried out collagen protein and is measured.
Influence (8 weekend) to degree of cirrhosis regulating liver-QI collagen content
Group degree of cirrhosis liver collagen content
-+++ +++average mg/g liver
1 0 0 0 9 3.0 30.1±6.5
2 6 0 0 0 0 14.5±1.8
3 1 3 1 2 1.75 20.3±2.7
The result shows: test 8 weekend the liver cirrhosis control animals all form liver cirrhosis, preparation of the present invention can be treated liver cirrhosis.
Concrete embodiment:
Embodiment 1: Flos Lonicerae 10, Radix Achyranthis Bidentatae 15, Radix Scrophulariae 15, Herba Erigerontis 20, medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct each 1.5 hours 2 times, filter, merging filtrate is concentrated into relative density 1.16, and adding ethanol is 60% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol, add 3% methylcellulose, add the moistening back of water and granulate, mixing incapsulates, and promptly gets capsule preparations.This product oral, three times on the one, each 2.
Embodiment 2: Flos Lonicerae 10, Radix Achyranthis Bidentatae 15, Radix Scrophulariae 15, Radix Notoginseng 20 is pulverized medicine, adds 6 times of water gagings and soaks 2 hours, decoct 2 times, each 1.5 hours, filter, merging filtrate is concentrated into relative density 1.16, and adding ethanol is 60% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leaves standstill, and gets supernatant, reclaim ethanol, add Shen base cellulose 3%, it is moistening to add water, makes granule, dry, add 2% carboxymethyl starch sodium, tabletting promptly gets tablet.
Embodiment 3: Flos Lonicerae 10, Radix Achyranthis Bidentatae 15, Radix Scrophulariae 15, Herba Erigerontis 10, Radix Notoginseng 10 are pulverized medicine, add 6 times of water gagings and soak 2 hours, decoct 2 times, each 1.5 hours, filter, merging filtrate is concentrated into relative density 1.16, and adding ethanol is 60% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol, add 2% low-substituted hydroxypropyl cellulose, it is moistening to add water, make granule, drying promptly gets granule.
Embodiment 4: Flos Lonicerae 80, Radix Achyranthis Bidentatae 85, Radix Scrophulariae 80, Herba Erigerontis 85 is pulverized medicine, adds 6 times of water gagings and soaks 2 hours, decoct 2 times, each 1.5 hours, filter, merging filtrate, be concentrated into relative density 1.16, adding ethanol is 60% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol, add the dissolving of injection water, regulate pH value to 7.5～8.0 with 10% sodium hydroxide solution, add injection water and 0.1% needle-use activated carbon, the mixed solution heated and boiled filters, and adds 0.1% sodium pyrosulfite and water for injection again to certain volume, filter, fill, sterilization promptly gets injection.
Embodiment 5: Flos Lonicerae 80, Radix Achyranthis Bidentatae 85, Radix Scrophulariae 80, Radix Notoginseng 85 is pulverized medicine, adds 6 times of water gagings and soaks 2 hours, decoct 2 times, each 1.5 hours, filter, merging filtrate, be concentrated into relative density 1.16, adding ethanol is 60% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol, add the dissolving of injection water, regulate pH value to 7.5～8.0 with 10% sodium hydroxide solution, add injection water and 0.1% needle-use activated carbon, the mixed solution heated and boiled filters, and adds sterile water for injection to full dose, vacuum lyophilization or aseptic filtration or spray drying or in organic solvent recrystallization, promptly get injection.
Embodiment 6: Flos Lonicerae 80, Radix Achyranthis Bidentatae 85, Radix Scrophulariae 80, Herba Erigerontis 30, Radix Notoginseng 55, the medicine pulverizing is added 3 times of water gagings soaked 1 hour, decocted 1 hour, filter merging filtrate, be concentrated into relative density 1.10, adding ethanol is 40% to containing the alcohol amount, leaves standstill, and gets supernatant, reclaim ethanol and be concentrated into relative density 1.20, adding ethanol is 70% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol, get extractum, adding distil water, syrup promptly gets oral liquid.
Embodiment 7: Flos Lonicerae 50, Radix Achyranthis Bidentatae 50, Radix Scrophulariae 50, Herba Erigerontis 50, the medicine pulverizing is added 10 times of water gagings soaked 5 hours, decoct 5 times, each 3 hours, filter, merging filtrate is concentrated into relative density 1.20, and adding ethanol is 70% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.40, adding ethanol is 90% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol, get extractum, splash into, promptly get drop pill with in the paraffin wax.
Embodiment 8: Flos Lonicerae 50, Radix Achyranthis Bidentatae 50, Radix Scrophulariae 50, Radix Notoginseng 50, the medicine pulverizing is added 3 times of water gagings soaked 1 hour, decocted 1 hour, filter merging filtrate, be concentrated into relative density 1.10, adding ethanol is 40% to containing the alcohol amount, leaves standstill, and gets supernatant, reclaim ethanol and be concentrated into relative density 1.20, adding ethanol is 70% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol, get extractum, add refined honey, pill promptly gets pill.
Embodiment 9: Flos Lonicerae 50, Radix Achyranthis Bidentatae 50, Radix Scrophulariae 50, Herba Erigerontis 40, Radix Notoginseng 10 is pulverized medicine, adds 6 times of water gagings and soaks 2 hours, decoct 2 times, each 1.5 hours, filter, merging filtrate is concentrated into relative density 1.16, and adding ethanol is 60% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leaves standstill, and gets supernatant, reclaim ethanol, dried cream powder is broken, and extract powder adds triglyceride (extractum: triglyceride=1: 55), 5%-10% glycerol (extractum: glycerol=1: 10), mixing, making content, is the capsule material with the gelatin, pill, drying promptly gets soft capsule.
Embodiment 10: Flos Lonicerae 50, Radix Achyranthis Bidentatae 50, Radix Scrophulariae 50, Herba Erigerontis 30, Radix Notoginseng 20 is pulverized medicine, adds 6 times of water gagings and soaks 2 hours, decoct 2 times, each 1.5 hours, filter, merging filtrate is concentrated into relative density 1.16, and adding ethanol is 60% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol, extractum adds pregelatinized Starch, (the pregelatinized Starch: be 1: 1 lactose=1: 2) of the mixed powder of lactose with the principal agent ratio, add 2% crospolyvinylpyrrolidone, mixing is that wetting agent is granulated with 95% ethanol, place, 60 ℃ of dryings, granulate adds 0.5% magnesium stearate and 5% crospolyvinylpyrrolidone, tabletting promptly gets dispersible tablet.
Embodiment 11: Flos Lonicerae 50, Radix Achyranthis Bidentatae 50, Radix Scrophulariae 50; Herba Erigerontis 10; Radix Notoginseng 40 is pulverized medicine, adds 6 times of water gagings and soaks 2 hours; decoct 2 times; each 1.5 hours, filter merging filtrate; be concentrated into relative density 1.16; adding ethanol is 60% to containing the alcohol amount, leaves standstill, and gets supernatant; reclaim ethanol and be concentrated into relative density 1.36; adding ethanol is 80% to containing the alcohol amount, leaves standstill, and gets supernatant; reclaim ethanol; dried cream powder is broken, and extract powder adds microcrystalline Cellulose, and (extract powder: microcrystalline Cellulose=2: 1), concentration is that 30～50% ethanol are wetting agent; concentration is that 3～5%PVP is a binding agent; put in the coating pelletizing machine, regulate coating granulator engine speed 100～120r; min; the blow rate required 10 * 10L/ml prepares Chinese medicine pellet, and molding time is 10～15min; after preparation finishes; continue round as a ball 1h, regulate 50 ℃～60 ℃ dryings of hot blast speed immediately, promptly get pellet.
Claims (13)
1, a kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease, it is characterized in that: calculate according to components by weight percent, it is mainly by Flos Lonicerae 10-80 weight portion, Radix Achyranthis Bidentatae 15-85 weight portion, Radix Scrophulariae 15-80 weight portion, one or both 20-85 weight portions in Herba Erigerontis, the Radix Notoginseng are made.
2, according to the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: calculate according to components by weight percent, it is mainly by Flos Lonicerae 50 weight portions, Radix Achyranthis Bidentatae 50 weight portions, Radix Scrophulariae 50 weight portions, one or both 50 weight portions in Herba Erigerontis, the Radix Notoginseng are made.
3, according to the Chinese medicine preparation of claim 1 or 2 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: described preparation is: injection, comprising: injection, powder pin, freeze-dried powder, tablet, dispersible tablet, capsule, soft capsule, pellet, granule, pill, powder, drop pill, slow releasing preparation, controlled release preparation, oral liquid, gel, soft extract, extractum and membrane.
4, according to the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 3, it is characterized in that: described preparation is: injection, comprising: injection, powder pin, freeze-dried powder, tablet, dispersible tablet, soft capsule, capsule, granule, pellet, drop pill, gel.
5, as the preparation method of the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 1-4, it is characterized in that: the medicine pulverizing is added 3～10 times of water gagings soaked 1～5 hour, decoct 1～5 time, each 1～3 hour, filter, merging filtrate is concentrated into relative density 1.10～1.20, adding ethanol is 60% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.20～1.40, adding ethanol is 80% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol, get extractum, make different preparations then respectively.
6, preparation method according to the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 5 is characterized in that: medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct 2 times, each 1.5 hours, filter merging filtrate, be concentrated into relative density 1.16, adding ethanol is 60% to containing the alcohol amount, leaves standstill, and gets supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leaves standstill, and gets supernatant, reclaim ethanol, add the dissolving of injection water, regulate pH value to 7.5～8.0, add injection water and 0.1% needle-use activated carbon with 10% sodium hydroxide solution, the mixed solution heated and boiled, filter, add sterile water for injection, add 10mg/ml mannitol again to full dose, vacuum lyophilization or aseptic filtration or spray drying or in organic solvent recrystallization, promptly get injection.
7, preparation method according to the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 5, it is characterized in that: medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct 2 times, each 1.5 hours, filter, merging filtrate is concentrated into relative density 1.16, adding ethanol is 60% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol, add the dissolving of injection water, regulate pH value to 7.5～8.0 with 10% sodium hydroxide solution, add injection water and 0.1% needle-use activated carbon, the mixed solution heated and boiled, filter, add 0.1% sodium pyrosulfite and water for injection again to certain volume, filter, fill, sterilization promptly gets injection.
8, according to the preparation method of the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 5, it is characterized in that: medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct 2 times, each 1.5 hours, filter merging filtrate, be concentrated into relative density 1.16, adding ethanol is 60% to containing the alcohol amount, leaves standstill, and gets supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leaves standstill, and gets supernatant, reclaim ethanol, add 2% low-substituted hydroxypropyl cellulose, it is moistening to add water, makes granule, drying promptly gets granule.
9, preparation method according to the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 5 is characterized in that: medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct 2 times, each 1.5 hours, filter, merging filtrate, be concentrated into relative density 1.16, adding ethanol is 60% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leaves standstill, get supernatant, reclaim ethanol, extractum adds pregelatinized Starch, (the pregelatinized Starch: be 1: 1 lactose=1: 2), add 2% crospolyvinylpyrrolidone of the mixed powder of lactose with the principal agent ratio, mixing, with 95% ethanol is that wetting agent is granulated, and places 60 ℃ of dryings, granulate, add 0.5% magnesium stearate and 5% crospolyvinylpyrrolidone, tabletting promptly gets dispersible tablet.
10; preparation method according to the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 5; it is characterized in that: medicine is pulverized; add 6 times of water gagings and soaked 2 hours, decoct each 1.5 hours 2 times; filter; merging filtrate is concentrated into relative density 1.16, and adding ethanol is 60% to containing the alcohol amount; leave standstill; get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount; leave standstill; get supernatant, reclaim ethanol, dried cream powder is broken; extract powder adds microcrystalline Cellulose (extract powder: microcrystalline Cellulose=2: 1); concentration is that 30～50% ethanol are wetting agent, and concentration is that 3～5%PVP is a binding agent, puts in the coating pelletizing machine; regulate coating granulator engine speed 100～120r; min; the blow rate required 10 * 10L/ml prepares Chinese medicine pellet; molding time is 10～15min, and preparation continues round as a ball 1h after finishing; regulate 50 ℃～60 ℃ dryings of hot blast speed immediately, promptly get pellet.
11, preparation method according to the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 5, it is characterized in that: medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct 2 times, each 1.5 hours, filter, merging filtrate is concentrated into relative density 1.16, adding ethanol is 60% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol, dried cream powder is broken, extract powder adds triglyceride (extractum: triglyceride=1: 55), (extractum: glycerol=1: 10), mixing is made content to 5%-10% glycerol, with the gelatin is the capsule material, pill, drying promptly gets soft capsule.
12, preparation method according to the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 5 is characterized in that: medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct 2 times, each 1.5 hours, filter, merging filtrate is concentrated into relative density 1.16, and adding ethanol is 60% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 80% to containing the alcohol amount, leave standstill, get supernatant, reclaim ethanol, add 2% low-substituted hydroxypropyl cellulose, it is moistening to add water, make granule, drying adds 2% carboxymethyl starch sodium, tabletting promptly gets tablet.
13, according to the preparation method of the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 5, it is characterized in that: medicine is pulverized, added 6 times of water gagings and soaked 2 hours, decoct 2 times, each 1.5 hours, filter merging filtrate, be concentrated into relative density 1.16, adding ethanol is 40～70% to containing the alcohol amount, leaves standstill, and gets supernatant, reclaim ethanol and be concentrated into relative density 1.36, adding ethanol is 70～90% to containing the alcohol amount, leaves standstill, and gets supernatant, reclaim ethanol, add 3% methylcellulose, add the moistening back of water and granulate mixing, incapsulate, promptly get capsule preparations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022513 CN1569161A (en) | 2004-05-10 | 2004-05-10 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022513 CN1569161A (en) | 2004-05-10 | 2004-05-10 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1569161A true CN1569161A (en) | 2005-01-26 |
Family
ID=34480172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410022513 Pending CN1569161A (en) | 2004-05-10 | 2004-05-10 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1569161A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872194A (en) * | 2012-10-09 | 2013-01-16 | 大连民族学院 | Traditional Chinese medicine decoction for treating ischemic cardiovascular and cerebrovascular diseases |
| CN104324138A (en) * | 2014-10-30 | 2015-02-04 | 宿州学院 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular disease and preparation method of traditional Chinese medicine composition |
| CN110123867A (en) * | 2019-05-27 | 2019-08-16 | 上海市同济医院 | It is a kind of to treat that immunocyte is unbalance, the Chinese medicine composition of the thrombotic diseases of heterocyst growth and its application |
-
2004
- 2004-05-10 CN CN 200410022513 patent/CN1569161A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872194A (en) * | 2012-10-09 | 2013-01-16 | 大连民族学院 | Traditional Chinese medicine decoction for treating ischemic cardiovascular and cerebrovascular diseases |
| CN104324138A (en) * | 2014-10-30 | 2015-02-04 | 宿州学院 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular disease and preparation method of traditional Chinese medicine composition |
| CN110123867A (en) * | 2019-05-27 | 2019-08-16 | 上海市同济医院 | It is a kind of to treat that immunocyte is unbalance, the Chinese medicine composition of the thrombotic diseases of heterocyst growth and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1299694C (en) | Flavone composition for sobering and liver protection and its use | |
| CN1569161A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1883638A (en) | Compound medicine for treating depression and method for preparing same | |
| CN1616060A (en) | A traditional Chinese medicine dripping pill preparation for promoting blood circulation and removing stasis, promoting qi and relieving pain | |
| CN1695711A (en) | Diphase capsule of compound dalbergia wood and preparation method | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1494902A (en) | Application of high-solubility berberine in preparation of medicine. | |
| CN1887283A (en) | Medicine composition containing bailobalide | |
| CN1522747A (en) | Medicament for treating coronary heart disease or coronary heart disease combined with cardiac insufficiency and preparation method thereof | |
| CN1895535A (en) | Chinese-medicinal preparation for treating gutture disease and it making method | |
| CN1569160A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1733071A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1857385A (en) | Medicine composition for treating cervical spondylosis and its preparing method | |
| CN1579495A (en) | Traditional Chinese medicine preparation for treating cardiovascular disease, preparation method and quality control method thereof | |
| CN1251718C (en) | Chinese medicine formula with treating and health function | |
| CN1247247C (en) | Apoplexy treating Chinese traditional medicine and its preparation | |
| CN1569159A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1730018A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and preparing process and application thereof | |
| CN1238042C (en) | Shoulder pain treating Chinese medicine and its prepn process | |
| CN1733061A (en) | Chinese medicinal preparation with astragalus root and erigeron breviscapus and application thereof | |
| CN1883585A (en) | Pharmaceutical composition for treating atherosclerosis and method for preparing same | |
| CN1698820A (en) | Dripping pills with jaundice eliminating liver protecting functions and its preparation method | |
| CN1689637A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1803182A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1634145A (en) | 'Xingnaojing' dripping pills for treating cephalitis and hepatic coma and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |